AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca ultomiris (ravulizumab) — Worldwide product sales ($M) ($M)
Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables
Latest, FY2025
4,718
Period ended Dec 31, 2025
Change on a year earlier
+20.2%
3,924 in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ultomiris (ravulizumab) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,718 | +20.2% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 3,924 | +32.3% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 2,965 | +50.9% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 1,965 | +185.6% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 688 | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Breakdown
What makes up ultomiris (ravulizumab) — worldwide product sales ($m)
- Ultomiris (ravulizumab) — Worldwide YoY actual (%)20.0% · FY2025
- Ultomiris (ravulizumab) — Worldwide YoY CER (%)19.0% · FY2025
- Ultomiris (ravulizumab) — US product sales ($M)2,667 · FY2025
- Ultomiris (ravulizumab) — Emerging Markets product sales ($M)261 · FY2025
- Ultomiris (ravulizumab) — Europe product sales ($M)1,053 · FY2025
- Ultomiris (ravulizumab) — Established RoW product sales ($M)737 · FY2025
Cite this data
StockData. (2026). AstraZeneca Ultomiris (ravulizumab) — Worldwide product sales ($M) ($M), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_ultomiris_world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.